# Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

Study · id `cardio:ct-nct03875183` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03875183](<https://clinicaltrials.gov/study/NCT03875183>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03875183

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT03875183. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-20 (actual); primary completion 2022-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT03875183, source copy `cardio:ctgov-nct03875183-2022-03-31`, retrieved 2026-10-26)
- Started: 2020-01-20 (actual) (ClinicalTrials.gov record NCT03875183, source copy `cardio:ctgov-nct03875183-2022-03-31`, retrieved 2026-10-26)
- Primary completion: 2022-12 (anticipated) (ClinicalTrials.gov record NCT03875183, source copy `cardio:ctgov-nct03875183-2022-03-31`, retrieved 2026-10-26)
- Completion: 2023-01 (anticipated) (ClinicalTrials.gov record NCT03875183, source copy `cardio:ctgov-nct03875183-2022-03-31`, retrieved 2026-10-26)
- Countries: United States; China (ClinicalTrials.gov record NCT03875183, source copy `cardio:ctgov-nct03875183-2022-03-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03875183-2022-03-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
- Acronym: TRACER-HF
- Condition: Heart Failure
- Condition: Reduced Ejection Fraction
- Intervention (Drug): INL1
- Intervention (Other): Placebo
- Lead sponsor: Innolife Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 7e813417b7682214d78d6e85b08e8be93aa548247a40534b2c041d38adefed67
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
